Presented By: DR - Biswajeeta Saha (1 Yr PG) Moderator: Dr. N. Sahu, Dept of Pathology, Kims, BBSR
Presented By: DR - Biswajeeta Saha (1 Yr PG) Moderator: Dr. N. Sahu, Dept of Pathology, Kims, BBSR
Presented By: DR - Biswajeeta Saha (1 Yr PG) Moderator: Dr. N. Sahu, Dept of Pathology, Kims, BBSR
PRESENTED BY: DR.BISWAJEETA SAHA(1ST YR PG) MODERATOR: DR. N. SAHU, DEPT OF PATHOLOGY,KIMS,BBSR
INTRODUCTION
First indication came in 1981 from New York and LA,of a sudden outbreak of two very rare diseases, Kaposi sarcoma and Pneumocystis carini pneumonia in young adults who were homosexuals or addicted to injected narcotics. This condition was named AIDS. Discovered independently by Luc Montagnier of France and Robert Gallo of the US in 1983-84
ROUTES OF TRANSMISSION
Icosehadral(20 sided) enveloped virus 90-120 nm in size Outer icosehedral shell and a inner core enclosing RNAs
PATHOGENESIS
Two major targets of HIV-immune system and central nervous system Profound cell mediated immunodeficiency is the hallmark Mainly affects CD4+Tcells,dendritic cells and macrophages. Enters body through mucosal tissues and blood--infects T cells,dendritic cells and macrophages--infection establishes in lymphoid organs---virus remains latent ----active viral replication associated with infection
In addition to direct killing of CD4+T cells,other mechanisms are: HIV cause progressive architectural and cellular destruction of lymph nodes Chronic activation of uninfected cells leads to activation induced cell death Loss of precursors of CD4+ T cells Fusion of infected and uninfected cells-leads to balloning and cell death Apoptosis of uninfected CD4+T cells by binding of soluble gp120 to CD4 moleculeactivation through T cell receptorby antigens
HIV1 can infect and multiply in terminally differentiated macrophages They are reservoirs of infection
Macrophages
Dendritic cells
Mucosal dendritic cells transport to regional lymph nodes Follicular ones are potent reservoir
B cells
Polyclonal activation ---germinal centre B cell hyperplasia, BM plasmacytosis, hypergammaglobulinimia, formation of circulating immune complexes
Preferential loss of activated and memory T cells Decreased delayed type hypersensitivity Susceptibility to opportunistic infection Susceptibility to neoplasm
Decreased chemotaxis and phagocytosis Decrease class II MHC expression Diminished capacity to present antigen to T cells
T CE
1 500cells/l
A1
2 200-499cells/l
A2
3 200cells/l
A3
B1
B2
B3
Fungal infection
Bacterial infections
Mycobacteriosis Nocardiosis
Viral infections
NEOPLASMS
Kaposis sarcoma
ORAL CANDIDIASIS
KAPOSI SARCOMA
10% body wt loss or cachexia with diarrhoea or fever or both,intermittent or constant,for atleast 1 month,not known to be due to a condition unrelated to HIV infection Cryptococcal meningitis Pulmonary/extrapulmonary TB Kaposis sarcoma Neurological impairment Candidiasis of esophagus Clinically diagnosed life threatening or recurrent episodes of pneumonia with or without etiological confirmation Invasive cervical cancer
LABORATORY INVESTIGATIONS
HIV POSITIVITY
It takes 6-12 weeks after infection for antibodies to rise to detectable levels.
ELISA
Antibodies detected in ELISA include those directed against: p24, gp120, gp160 and gp41, detected first in infection and appear in most individuals Standard blood screening test
Sensitivity->99.5%
4th generation EIA test combine detection of Abs to HIV with detection of p24 Ag for HIV False positive EIAAbs to class II Ag Auto antibodies Hepatic disease Recent influenza Acute viral infections So EIA confirmed by western blot, p24 Ag capture assay or HIV RNA tests.
WESTERN BLOT
Most popular confirmatory test
Antibodies to gp31, gp41, gp 120, and gp160 appear later but are
Advantage-multiple antigens elicit production of specific antibodies and can be detected as discrete bands on western blot
Interpretation of results.
No bands, negative. In order to be interpreted as positive a minimum of 3 bands directed against the following antigens must be present: p24, p31, gp41 or gp120/160. CDC criteria require 2 bands of the following: p24, gp41 or gp120/160
INDIRECT IMMUNOFLOURESCENCE
P24 antigen only present for short time, disappears when antibody to p24
appears. Greatest use as a screening test for persons suspected to have acute HIV syndrome. Test not recommended for routine screening as appearance and rate of rise are unpredictable. Sensitivity lower than ELISA.
early infection suspected in seronegative patient newborns CSF monitoring disease progress
Routine blood donor screening is done by nucleic acid testing. 3 assays are used where measurement of anti HIV Ab may be misleading RT-PCR Branched DNA Nucleic acid sequence based amplification (NASBA)
USEDiagnosis Initial prognosis Determining need for therapy Monitoring effects of therapy
VIRUS ISOLATION
Virus isolation can be used to definitively diagnose HIV. Best sample is peripheral blood, but can use CSF, saliva, cervical
Viral load or viral burden is the quantity of HIV-RNA that is in the blood. RNA is the genetic material of HIV that contains information to make more virus. Viral load tests measure the amount of HIV-RNA in one milliliter of blood. Take 2 measurements 2-3 weeks apart to determine baseline. Repeat every 3-6 months in conjunction with CD4 counts to monitor viral load and T-cell count. Repeat 4-6 weeks after starting or changing antiretroviral therapy to determine effect on viral load.
TESTING OF NEONATES
Use tests to detect IgM or IgA antibodies, IgM lacks sensitivity, IgA
more promising. Measurement of p24 antigen. PCR testing may be helpful but still not detecting antigen soon enough: 38 days to 6 months to be positive
IgM & IgA in infants are assayed (but not reliable in 1st 3 mths after
birth) HIV DNA PCR- diagnostic at 1 mth of age
TREATMENT
Major causes of morbidity are-cancer,accelerated cardiovascular diseases,kidney diseases and liver diseases.
PREVENTION
THANK YOU